Publications (10) Norma Carmen Gutiérrez Gutiérrez publications

filter_list Transplantation

2024

  1. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  2. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  3. Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options

    Journal of Clinical Medicine, Vol. 13, Núm. 1

2021

  1. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5

2020

  1. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

    Blood Cancer Journal, Vol. 10, Núm. 10

2017

  1. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO)

    Annals of Hematology, Vol. 96, Núm. 8, pp. 1323-1330

  2. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma

    Haematologica, Vol. 102, Núm. 5, pp. 922-931

2007

  1. Phase II pethema trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: Efficacy and clinical implications of tumor response kinetics

    Journal of Clinical Oncology, Vol. 25, Núm. 28, pp. 4452-4458

  2. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis

    Leukemia, Vol. 21, Núm. 1, pp. 143-150

1999

  1. Hematopoietic damage prior to PBSCT and its influence on hematopoietic recovery

    Haematologica, Vol. 84, Núm. 6, pp. 511-516